Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02949752|
Recruitment Status : Active, not recruiting
First Posted : October 31, 2016
Last Update Posted : February 18, 2020
|Condition or disease||Intervention/treatment||Phase|
|Antipsychotics Weight Gain||Drug: Aripiprazole||Phase 4|
The metabolic syndrome (MetS) is a well described cluster of interrelated risk factors for developing cardiovascular disease and type 2 diabetes. The main components of MetS are central obesity, hypertension, hyperglycaemia and dyslipidaemia. Individuals with MetS are two to three times more likely to have a heart attack or stroke and five times more likely to develop type 2 diabetes than those without. Metabolic abnormalities have often been identified in individuals with schizophrenia. Since the introduction of second generation antipsychotics, evidence has accumulated of their link with metabolic abnormalities. An abnormality in glucose metabolism, particularly diabetes mellitus (DM), has received the most attention. Other conditions such as cardiovascular morbidity, abnormal lipid metabolism and obesity also have a serious impact on the physical health of individuals with schizophrenia. Several pharmacological strategies are under investigation for countering the metabolic side effects, of which antipsychotic Aripiprazole has shown good evidence, when switched to as monotherapy, and also as an adjunct .
The study is planned as an open label study. An open label exploratory design will help test the hypothesis that use of adjunct Aripiprazole can help with reducing weight gain on atypical antipsychotics, and improve metabolic parameters. The number of patients in each arm is designed to yield an 80% power to detect significant differences in weight from baseline at P<0.05. There is no randomisation, blinding or placebo control, as this study is planned to test the initial hypothesis, which can inform further RCT's, if results are encouraging.
Participants will initially be screened to ensure that they fulfil the inclusion criterion, and eligible participants will be entered into the 12 week study, where they will be prescribed 5 mg Aripiprazole per day, in addition to their routine atypical antipsychotic. The typical dose range of the routine atypical antipsychotics are clozapine 200-450 mg, olanzapine 5-20mg and risperidone 2-16mg respectively. During the 12 week study, the dose of the antipsychotic and Aripiprazole should stay unchanged. If the clinical situation warrants a change in dose of antipsychotic or switch of antipsychotic, the participant will be withdrawn from the study. Atypical antipsychotic other than the ones under investigation will be prohibited, as well as medications or supplements for weight loss or weight gain, or medications known to have substantial propensity for weight changes. Benzodiazepines, anticholinergics, sleep aides will generally be allowed. Antidepressants and mood stabilisers at a stable dose, which patients were receiving prior to the study, will be allowed. Patients at high risk of suicide or self-harm as assessed by the study investigator, will be withdrawn from the study, as well as those with significant side effects from adjunct Aripiprazole.
The primary objective of the study is to assess mean change of weight from the baseline after use of adjunct Aripiprazole. The secondary endpoints include changes in metabolic parameters (waist circumference, fasting blood glucose, HbA1c, total, HDL and LDL cholesterol levels).Safety and tolerability will be measured by Simpson Angus Scale (SAS total score), Side Effects Checklist, Barnes Akathisia Scale (BAS), Abnormal Involuntary Movement Scale (AIMS), adverse events or serious adverse events reports.
The study will also evaluate neurocognition via a brief battery of 2 tests - the digit sequencing and symbol coding. These 2 tasks have been shown in a previous study to explain 76% of the variance of global neurocognition in a large sample of patients with schizophrenia. In our local sample, it was similarly shown that these 2 tasks are valid, representing 72% of the variance in global neurocognition in schizophrenia (unpublished results). The avoidance of a language component in these 2 tasks is a significant strength in choice of cognitive tasks as has been previously shown that the local population tend to underperform on language-based cognitive tasks.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||67 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile|
|Actual Study Start Date :||August 2016|
|Actual Primary Completion Date :||October 1, 2019|
|Estimated Study Completion Date :||May 1, 2020|
Experimental: Aripiprazole Adjunct
Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics
Aripiprazole 5 mg every morning will be prescribed for 12 weeks
- Mean change in body weight in kilograms [ Time Frame: 12 weeks, assessed at baseline and at final follow up at week 12 ]To assess mean change in body weight from baseline to week 12 in patients receiving adjunctive Aripiprazole to atypical antipsychotic therapy, i.e. olanzapine, clozapine, risperidone.
- Change in waist circumference in cm [ Time Frame: 12 weeks, assessed at baseline and at final follow up at week 12 ]To evaluate change in waist circumference from baseline to week 12
- Number of participants with treatment-related adverse events as assessed by Side Effects Checklist [ Time Frame: Checklist completed every two weeks, for the study duration of 12 weeks via Face to Face interview or Telephone contact ]To evaluate safety and tolerability data on adjunctive use of Aripiprazole using side effect checklist
- Number of participants with improvement or deterioration in neuro-cognition as assessed by Digit Sequencing Test and Symbol Coding Test [ Time Frame: 12 weeks, assessed at baseline and at final follow up at week 12 ]To evaluate changes in neuro-cognition from baseline to week 12
- Change in fasting plasma glucose mg/dl from baseline to week 12 [ Time Frame: 12 weeks, assessed at baseline and at final follow up at week 12 ]To evaluate change in fasting plasma glucose mg/dl from baseline to week 12
- Change in Total Cholesterol, LDL and HDL Cholesterol mg/dl from baseline to week 12 [ Time Frame: 12 weeks, assessed at baseline and at final follow up at week 12 ]
- Change in HbA1c (%) from baseline to week 12 [ Time Frame: 12 weeks, assessed at baseline and at final follow up at week 12 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02949752
|Institute of Mental Health|
|Singapore, Singapore, 556121|
|Principal Investigator:||Bhanu Gupta, MRCPsych||Institute of Mental Health, Singapore|